New Insights into Neurodegeneration at the Ubiquitin Drug Discovery & Diagnostics Conference 2011

March 22, 2011 - PRLog -- The prognosis of neurodegenerative diseases like Parkinson's is intricately linked to our ability to correctly diagnose these diseases. Recently, ubiquitin pathway enzymes have been implicated in neuronal functions - in particular, ubiquitin carboxy-terminal hydrolase L1, or UCH-L1, which was first discovered by Dr. Keith Wilkinson of Emory University and which comprises around one to two percent of the total protein in the brain. Because of its prevalence in neuronal cells, it is closely linked to many of these disorders. It is released in significant quantities from injured or damaged neurons, and can also be used as a biomarker for these conditions, making them easier to identify and consequently easier to treat and manage.

Dr. Wilkinson will feature as a keynote speaker at the upcoming Ubiquitin Drug Discovery & Diagnostics Conference in Philadelphia. This premier conference, to be held from July 11th to 13th at the Four Seasons Hotel, will feature groundbreaking research and insight into the ubiquitin pathway and its many potential applications to the treatment of human diseases including Parkinson's, Alzheimer's, and others.

Participants are encouraged to register for the event at www.ubiquitinconference.com as soon as possible, as last year's event was sold out.

Contact Details: Varsha Luthra
Director, Ubiquitin Conferences
luthra@ubiquitinconferences.com
610-644-0585, ext. 319

www.ubiquitinconference.com